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ABSTRACT 
This review provides a general overview on the positivity and persistence of Zika virus 
(ZIKV) in female genital tract (FGT) of non-pregnant women and animals, as well as in 
cell cultures, and its influence on FGT health. We performed a systematic review based 
on the PRISMA statement to identify studies focused on “Zika virus” and “non-pregnant 
female” in PubMed, Embase, Scopus Scholar and Web of Knowledge databases of full-text 
papers and abstracts published in English, with no restrictions regarding the initial date of 
publication, up to August 2019. Our search terms yielded 625 records, that were 108 after 
removal of duplicates, leaving 517 items for title and abstract reviews. Of these, 475 did 
not meet the inclusion criteria, leaving 42 records for full-text review and resulting in the 
exclusion of 6 additional records. The remaining 36 met our inclusion criteria. Variations 
were observed regarding the presence and persistence of ZIKV in lower and upper genital 
samples. However, the FGT was the place in which ZIKV RNA has been detected, sometimes 
for relatively long periods, even after the clearance from blood and urine. In addition to the 
vagina and cervix, the endometrium, uterus and ovary (oocytes and follicles) could also be 
involved in persistent ZIKV infections. Further prospective studies are needed to assess the 
effect of ZIKV on FGT health. 
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INTRODUCTION
Zika virus (ZIKV) is an arbovirus belonging to the genus flavivirus (family 
Flaviviridae) along with Japanese encephalitis virus (JEV), West Nile virus (WNV) 
and dengue virus (DENV), all of them are medically important viruses transmitted 
by mosquitoes or ticks1. The first human ZIKV infection was described in Nigeria, 
in 19542, after its isolation from a rhesus monkey in Uganda, in 19473. Very few 
reports of infections were subsequently identified until the virus outbreak in 
2007 in Yap Island Federal State of Micronesia4,5 and later in French Polynesia6,7. 
Afterwards, ZIKV was introduced in Brazil in late 2013, early 20148, with an 
epidemic spread occurring throughout the Americas in 20159. In January 2018, the 
Pan American Health Organization (PAHO) reported 223,477 confirmed cases of 
ZIKV infections that have increased worldwide between 2015 and 201810. Despite 
the global distribution of ZIKV, there are no clinically approved vaccines or specific 
treatments available11. 
It has been widely reported that approximately 80% of ZIKV-infected patients are 
asymptomatic5. However, symptoms including myalgia, headache, mild fever, rash, 
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arthralgia, arthritis, conjunctival hyperemia and edema, 
with symptoms lasting for several days to weeks, have 
been reported1. Following the 2016 outbreak, a number of 
studies suggested that ZIKV infection in pregnant women 
was associated with congenital abnormalities, such as 
microcephaly, and may also be a trigger for Guillain-Barré 
syndrome12,13.
The primary route of ZIKV transmission is a human-
mosquito-human cycle in urban and peri-urban environments. 
The transmission occurs through the bite of infected Aedes 
species mosquitoes, mainly Aedes aegypti and Aedes 
albopictus, but the virus was isolated in many other 
Aedes species14. Other non-mosquito ZIKV transmission 
routes have been reported, such as maternal-fetal12,13, 
by blood transfusion15 and through sexual contact16,17 . 
ZIKV ribonucleic acid (RNA) has been detected in the 
blood, saliva, urine, cerebrospinal fluid, semen, breast 
milk18,19, vagina and cervix, but ZIKV dynamics in body 
fluids is not well understood20,21. In the context of ZIKV 
sexual transmission, there are several reports of male-to-
female16,17,22-25 and male-to-male26 transmission, but few 
studies showing female-to-male transmission27.
Evidence of sexual transmission prompted the 
investigation of male and female reproductive tracts as 
ZIKV reservoirs28. Several groups have demonstrated that 
ZIKV exhibits tropism for the male reproductive tract 
and causes inflammation leading to structural damage 
and breakdown of the blood-testis barrier in mice29-31. 
The longest persistence of detectable ZIKV in semen 
was reported by Barzon and colleagues32 who reported 
ZIKV-RNA detection up to 370 days post the onset of 
symptoms (dpo). Another studydetected the presence of 
viruses in semen up to 69 dpo22. Identification of ZIKV 
RNA has been associated with genitourinary symptoms 
and oligospermia23,33,34. In females, ZIKV RNA has been 
detected in cervical mucus and vaginal secretions at some 
time points after the clearance from blood35-37. ZIKV RNA 
has also been detected in the ovaries of female mice38-40 and 
non-human primates41. A human case of in vitro fertilization 
(IVF) described ZIKV RNA-positive oocytes42. However, in 
comparison with the male genital tract, the consequences of 
ZIKV infection on the female genital tract (FGT) have not 
been extensively evaluated, so that little is known about the 
target cells of ZIKV in this site. Furthermore, most studies 
have evaluated ZIKV infections in pregnant womens’ 
FGT due to the relationship between ZIKV and congenital 
abnormalities. Thus, several important questions about 
ZIKV-RNA detection in the FGT of non-pregnant women 
and animals need to be answered, such as: does the virus 
have tropism for any specific FGT cell? What is the viral 
load and how long does the virus remain infectious? How 
long women need to wait to become pregnant after ZIKV 
infections? What is the long-term damage to women? 
In this review, we summarized the current knowledge 
of ZIKV infections in the FGT of non-pregnant women and 
animals and the influence of ZIKV on the health and fertility 
of FGT, as well as the effects of ZIKV infections on assisted 
reproduction. This review provides a general overview of 
the positivity and persistence of ZIKV infections in the 
FGT of non-pregnant women and animals, as well as in 
cell culture, and its influence on FGT health. 
METHODS
A review was conducted following a systematic search 
based on the PRISMA statement43 to identify studies 
focused on “Zika virus” and “non-pregnant female” in 
PubMed, Embase, Scopus Scholar and Web of Knowledge 
(WOK) databases of full-text papers and abstracts published 
in English, with no restrictions regarding the initial date of 
publication, up to August2019. The strategy searched for 
publications by using MeSH Terms grouped in two blocks. 
(1) “Zika virus” and “Zika virus infection” “arboviruses” 
“arbovirus infection” (2) “vagina”, “cervix uteri”, “uterus”, 
“ovary”, “peritoneum”, “fallopian tubes”, “cell culture 
techniques”, “animal experimentation”, “genitalia female”. 
The identification of relevant studies written in English was 
performed independently by all of the authors. In addition, 
the reference lists of selected papers were also searched for 
additional relevant publications. Epidemiology bulletins 
from the Center for Disease Control and Prevention (CDC) 
were also included.
Abstracts were carefully selected by all independent 
reviewers to ensure the publications’ originality, quantitative 
and qualitative consensus. The studies initially selected had 
to fit three criteria. The first criterium included original 
epidemiological, clinical and experimental studies involving 
humans, animals and cells and/or reconstructed epithelium. 
The second criteriumwas to exclude duplicate studies and 
review studies. The third criterium involved the screening of 
eligible publications on the genital tract. After a consensual 
analysis, the papers most closely related to the theme 
descriptors were selected. Then, the articles were randomly 
distributed to all the investigators who acted as independent 
evaluators in charge of the inclusion of papers in the final 
cohort, for data extraction. To increase the sensitivity of the 
search, the references of the original articles were carefully 
reviewed to retrieve articles that could be additionally 
included in this review. To ensure that all relevant data from 
each paper were included in the review, a final consensus 
was achieved following an additional examination of the 
full texts by two additional experts (MELC and VRSS). 
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RESULTS
Our search terms yielded 625 records, 108 were 
removed due to duplication leaving 517 for title and abstract 
reviews. Of these, 475 did not meet the inclusion criteria, 
leaving 42 records for the full-text review, resulting in 
the exclusion of six additional records. The remaining 
36 records met our inclusion criteria and were included in 
this review (Figure 1). These studies fell into three broad 
categories: ZIKV kinetics in FGT of non-pregnant women 
(n=12), in vivo ZIKV models in FGT of non-pregnant 
animals (n=14), and in vitro ZIKV cellular models in FGT 
(n=10) (Tables 1 and 2).
ZIKV kinetics in FGT of non-pregnant women
The majority of the studies evaluated ZIKV shedding 
in FGT of non-pregnant women using lower genital tract 
samples (LGT)21,25,35-37,44-48. Very few samples from the 
upper genital tract (UGT) have been studied42,49 (Table 1).
Regarding the LGT studies, the first case of ZIKV 
RNA in vaginal and cervical samples of a non-pregnant 
woman was described by Prisant et al.35. They presented 
the case of a 27-year-old woman from Guadeloupe (French 
territory in the Caribbean) during the 2016 outbreak of 
ZIKV in that region. The patient presented with clinical 
symptoms suggestive of an arbovirus infection, such as 
fever, maculopapular rash and conjunctivitis. The diagnosis 
of ZIKV infection was performed by real-time reverse 
transcription-polymerase chain reaction (RT-PCR) in a 
positive blood sample, while a urine sample was negative. 
Vaginal, cervical and endocervical samples were collected 
for ZIKV RNA analysis 3 dpo and they were positive. On 11 
dpo, blood and urine samples were negative for ZIKV RNA, 
while the cervical mucus remained positive. According to 
the authors, the persistence of viral RNA in the vaginal and 
endocervical samples is of major importance in view of the 
risk of mother-to-fetus vertical transmission. 
Subsequently, some studies have reported the presence 
and persistence of ZIKV RNA in the vaginal and/or cervical 
samples of non-pregnant women21,25,36,37,44-48. In these 
studies, the authors reported data on the symptoms, and 
the variability on the period of viral RNA detection and 
persistence in vaginal and/or cervical samples. 
Figure 1 - Flowchart of the steps performed in this systematic review.
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Penot et al.45 described the case of a 40-year-old French 
woman with controlled HIV infection, who had recently 
returned from a trip to the Caribbean-French Islands. She 
reported asthenia, myalgia, and developed abdominal pain, 
diarrhea and a pruritic rash on the face, chest, back and arms 
two days later. On the physical examination, the patient 
had generalized maculopapular pruritus, conjunctival 
hyperemia, fever (38.1 °C), asthenia and intense diffuse 
myalgia. The diagnosis was performed by RT-PCR and 
was negative for dengue and chikungunya. ZIKV RNA was 
positive in the plasma, urineand vaginal secretions 3 dpo. 
The viral RNA load was 3.8 log copies/mL in plasma, 
6.1 log copies/mL in urine, 5.3 log copies/mL in vaginal 
sample 1 (collected by swab) and 3.9 log copies/mL in 
vaginal sample 2 (collected after instilling 5 mL of saline 
solution between the cervix and the posterior vaginal wall). 
The two vaginal samples were inoculated into Vero cell 
cultures and C6/36 cells lineage derived from A. albopictus, 
and ZIKV was isolated from both cultures, demonstrating 
the presence of infective ZIKV. The patient consented to 
collect another vaginal swab and cervical mucus on 10 dpo, 
and both samples were negative for ZIKV RNA. The authors 
considered unlikely that the HIV-1 infection had influenced 
the evolution of ZIKV infection, as the initial symptoms 
were similar to the ones of HIV-negative patients. Moreover, 
the results suggested a short period of infectivity of women 
with acute ZIKV infections through their genital secretions. 
Murray et al.36 have already reported the presence of ZIKV 
RNA in vaginal samples of a 26-year-old patient who visited 
Honduras, up to 14 dpo. She presented with rash, fever, 
headache and conjunctivitis. Diagnosis was performed by 
RT-PCR and ZIKV was detected in serum samples up to 8 
dpo and in other body fluids up to 14 dpo, including vaginal 
secretions. In serum samples, ZIKV was detected until 81 
dpo. According to the authors, the presence of ZIKV RNA 
in vaginal secretions is a risk for sexual or intrapartum 
transmission, during a relatively long period.
Nicastri et al.41 reported the case of a nurse who 
worked as a volunteer and raveled from Italy to Santo 
Domingo in the Dominican Republic. After her return, she 
presented with symptoms compatible with ZIKV infection 
and tested positive for ZIKV RNA in a vaginal swab up 
to 13 dpo. Besides, serum (7 dpo), urine (up to 27 dpo), 
cerebrospinal fluid (6 dpo) and saliva (up to 13 dpo) 
were positive for ZIKV RNA. Sánchez-Montalvá et al.25 
performed a prospective study in two Spanish centers in 
2016. Among four non-pregnant women, one tested positive 
for ZIKV RNA in vaginal swabs collected during the first 
45 dpo and the viral clearance occurred between 37 and 69 
dpo. As this study involved the investigation of ZIKV in 
different biological fluids of men and women, few details 
were available regarding the positivity of ZIKV in vaginal 
secretions. However, the authors did not identify any sexual 
transmission among the investigated sexual partners by 
serological testing. 
Tobar et al.46 performed RT-PCR, including ZIKV, 
on cervical samples from the gynecological service of a 
hospital in Guayaquil, Ecuador. This work was part of a 
Table 1 - Timeline of reports evaluating the kinetics of ZIKV in the lower genital tract of non-pregnant women. 
Authors
ZIKV vaginal 
and/or cervical 
last detection 
(dpo)*
ZIKV 
RT-PCR**
Blood ZIKV 
load**
Urine ZIKV 
load**
ZIKV isolation 
from vaginal 
secretion 
Prisant et al.35 ~11 Positive Negative Negative NA
Penot et al.45 ~3-10 Sample 1: 
5.3 log copies/mL 
Sample 2: 
3.99 log copies/mL
3.8 log copies/mL 6.1 log copies/mL Positive
Murray et al.36 14 Positive Positive Positive NA
Nicastri et al.44 13 Positive Negative Positive NA
Sánchez-Montalvá et al.25 ~37-69 Positive NI NI NA
Paz-Bailey et al.21 ~3 Positive NI NI NA
Tozetto-Mendoza et al.48 ~18 Positive Positive NI NA
Tobar et al.46 NI Positive NA NA NA
Reyes et al.47 180 Positive NI NI NA
Cruz et al.37 ~31-54 2 × 102 copies/mL Negative Negative NA
NI: not informed; NA: not analyzed; ZIKV: Zika virus; RT-PCR: real-time reverse transcription–polymerase chain reaction. *dpo: 
days post onset of symptoms; **On the day of the last detection of ZIKV RNA in lower genital tract.
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larger study on the presence of ZIKV in different body 
fluids. From the total of 89 samples, 19 were diagnosed 
as atypical squamous cells of undetermined significance 
(ASCUS) in cytological exams. From these, five were 
positive for ZIKV and five were positive for HPV, and there 
were no co-infections. The authors concluded that, given 
the presence of ZIKV RNA and the absence of HPV DNA 
in cervical samples diagnosed as ASCUS, it is plausible 
that ZIKV could be a triggering factor for the induction of 
cellular damage observed in these cells.
The study of Reyes et al.47, from October 2016 to 
November 2017, recruited women ≥18 years old with 
symptoms suggestive of ZIKV infections (any combination 
of rash, fever, and conjunctivitis for ≤7 days), who attended 
a public health center and an University Hospital in 
Nicaragua. Five women were enrolled in a prospective 
cohort to characterize the duration of viral shedding in FGT. 
Blood, urine, saliva and vaginal samples were collected. 
The five women with acute ZIKV infections provided at 
least one vaginal secretion. Four women were pregnant; 
gestational age at enrollment was 1–8 months. The infants 
of all four women were healthy at birth, with no obvious 
congenital anomalies. However, the authors did not describe 
the specific results of the participating non-pregnant women. 
Table 2 - Animal models of ZIKV infection in non-pregnant female genital tract. 
Authors Animal model Inoculation route Female genital tropism
Positive biological 
fluids
Osuna et al.52 Rhesus and Cynolmogus Monkeys Subcutaneous
Vagina 
Cervix 
Uterus 
Ovary
Blood 
Urine 
Salive 
Cervical-vaginal lavage
Hirsch et al.59 Rhesus Monkeys Subcutaneous Uterus Vagina
Blood 
Urine
Haddow et al.57 Rhesus and Cynolmogus Monkeys 
Vaginal 
Retal NI Blood
Carroll et al.41 Rhesus Monkeys Vaginal  Subcutaneous
Vagina 
Cervix 
Uterus 
Ovary
Blood 
Urine 
Cervical-vaginal lavage
Dowall et al.38 WT 129Sv/Ev and A129 type I INF-deficient mice Subcutaneous Ovary Blood
Duggal et al.40 IFN α/β and -γ receptor-knockout AG129 mice
Vaginal 
Subcutaneous 
Sexual
Ovary 
Ovarian follicles Blood
Tang et al.55
AG129 and 
LysMCre+IFNARfl/fl 
C57BL/6 mice
Vaginal Vagina Serum
Broughton et al.56 C57BL/6 mice Subcutaneous Ovary Serum
Hastings et al.58
WT,Axl-/-, Mertk-/-, 
Axl-/- Mertk-/-, and 
Axl-/- Tyro3-/- mice
Subcutaneous
 
Vaginal 
Intracraneal
Vagina NI
Khan et al.53 WT mice Vaginal Vagina NI
Scott et al.61 WT C57BL/6 mice Subcutaneous
Vagina 
Cervix 
Uterine horns 
Ovary
Serum
Winkler et al.60 Ifnar1-/- and Rag-/- mice Sexual Vagina Plasma 
Caine et al.28 Ifnlr1−/−, Ifnar1−/−WT 
and WT C57BL/6J mice Vaginal
Vagina 
Cervix 
Uterus
NI
Caine et al.62
WT, congenic CD8−/− 
and TCRβδ−/− C57BL/6 
mice
Subcutaneous Ovary Serum
NI: not informed; WT: wild type
Morelli et al.
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Nevertheless, the study had unprecedented results, with 
ZIKV-RNA detection in vaginal secretions between 60 
and 180 dpo. 
A study conducted by Paz-Bailey et al.21 prospectively 
assessed a cohort of newly infected people in Puerto Rico. 
Only two of 119 women (1.6%) had ZIKV RNA in vaginal 
secretions (one was an asymptomatic participant and one 
was positive on 3 dpo). In this study, half of the participants 
had detectable viral RNA in urine for at least one week, in 
serum for two weeks, and in semen for more than one and a 
half months, while 5% or less had detectable ZIKV RNA in 
urine for five weeks, in serum for six weeks, and in semen 
for four months. Conversely, ZIKV RNA was seldomly 
detected in saliva and vaginal secretions. 
Cruz et al.37 detected ZIKV RNA in vaginal secretions 
and in endocervical samples for up to 31 dpo. Interestingly, 
in this case report, ZIKV RNA remained positive in the 
vaginal secretions and endocervical samples, but in urine, 
saliva, plasma, serum and whole blood, the viral detection 
was negative on 31 dpo. The authors raised the hypothesis 
of a possible association between ZIKV and vaginal and 
endocervical epithelial cells, evidencing that, like in semen, 
variations in positivity rates found in FGT secretions and 
the persistence of the virus may occur.
Finally, the study of Tozetto-Mendoza et al.48 evaluated 
symptomatic ZIKV-infected individuals identified in 
two hospitals in Sao Paulo State, Brazil. Patients were 
investigated regarding their clinical characteristics, viral 
shedding in body fluids and serodynamics. Ninety-four of 
235 symptomatic patients had ZIKV infection confirmed 
by RT-PCR. Shedding in genital fluids and saliva was rare. 
Ten women were tested at least once for ZIKV in genital 
fluids, and only one had a positive RT-PCR result. This 
patient was a 26-year-old non-pregnant participant who 
was enrolled 3 dpo with rash, headache and arthralgia 
and had a cervicovaginal sample collected on 18 dpo. 
The vaginal fluid and a plasma sample were positive for 
ZIKV. Moreover, genital fluid samples were collected from 
16 women with confirmed ZIKV infection, with a median 
of 12 months after enrollment, and none tested positive for 
ZIKV by RT-PCR.
As far as we know, only two studies detected ZIKV 
shedding in the upper genital tract (UGT) of non-pregnant 
women. Prisant et al.49, in a controlled observational clinical 
study, followed up 179 female patients undergoing oocyte 
vitrification cycles in an university fertility center during 
the ZIKV epidemic in French Territories in America. At 
that time, the French Ministry of Health banned medically-
induced pregnancies. Oocyte vitrification cycles were the 
only means to preserve fertility options and to ensure the 
freezing of ZIKV-free oocytes for currently exposed and/or 
recently infected patients. Samples of serum, urine, LGT, 
endometrium, follicular fluid and immature oocytes 
were tested for ZIKV RNA by RT-PCR. ZIKV RNA 
was not detected in various samples of exposed patients. 
Furthermore, no ZIKV RNA was detected in the genital 
tracts of women with a recent (3 months) history of acute 
infection. In this study, there was a lack of ZIKV RNA 
persistence in FGT of ZIKV-exposed and/or recently 
infected women in reproductive age. 
The second study on UGT of non-pregnant women 
was performed by Filho et al.42 and described a case of a 
37-year-old female who underwent in vitro fertilization 
(IVF). She developed a skin rash on her trunk and limbs 
during the treatment. RT-PCR results were positive for 
ZIKV in a blood sample and negative in her husband’s 
blood and semen. Oocyte aspiration was performed, 
retrieving seven oocytes, follicular fluidand cumulus 
cells. ZIKV RT-PCR results for the follicular fluid and 
cumulus cells were negative, but results were positive 
for two oocytes. This was the first report in the literature 
analyzing ZIKV in oocytes, follicular fluid, and cumulus 
cells. For these authors, the presence of ZIKV RNA in 
two oocytes showed the importance of testing couples 
seeking assisted reproductive technology (ART) because 
of the real risk of the embryo contamination. 
Overall, among the cases and studies described, there 
are variations regarding the presence and persistence of 
ZIKV in LGT samples of non-pregnant women. However, 
it is unanimous that FGT is the place in which ZIKV RNA 
has been mostly detected, and in some cases for relatively 
long periods, even after the clearance from blood and urine. 
Similarly, there is extensive literature on the persistence 
of ZIKV in semen, with reports of viral positivity up to 
370 days32. Thus, it is possible that FGT can also act as 
a sanctuary for ZIKV survival, allowing and extending 
the risk of sexual transmission. However, regarding UGT, 
further studies are needed to determine the current infection 
rate, as well as the kinetics of ZIKV infection. However, 
these reports evidenced that ZIKV shedding in FGT remains 
remains poorly studied but is a serious question due to its 
potential for sexual transmission from female-to-male, 
damaging the reproductive health of non-pregnant women, 
as well as favoring ascending fetal infections in pregnant 
women. This evidence supports the recommendation of safe 
sex practices for women returning from areas with ongoing 
ZIKV transmission. Nevertheless, the reasons for ZIKV 
persistence in FGT remain unknown and need clarification, 
but factors such as the magnitude of viral load, previous 
flavivirus infections and host-virus interactions should be 
taken into account. 
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In vivo ZIKV models in the FGT of non-pregnant 
animals
Several animal studies28,41,50-62 tried to elucidate ZIKV 
viral dynamics aiming at observing the distribution of the 
virus in tissues and the triggered immune response, as 
well as the damage to tissues, including FGT (Table 2). 
The majority of animal studies were performed in small 
animals, such as mice28,50,53,55,56,58,60-62, but there are studies 
in non-human primates (NHPs)41,52,57,59.
In vivo ZIKV models in FGT of non-pregnant NHPs 
The physiology of NHPs is close to that of humans, 
and a human scenario of ZIKV infection can be simulated 
in these models, despite the difficulties of acquisition and 
maintenance of NHPs. These models are of great relevance 
to increase the knowledge on pathogenesis and immunity, 
as well as on strategies to develop vaccines and therapies 
against ZIKV52.
In these NHPs models, ZIKV subcutaneously inoculated 
were designed to mimic mosquitoes transmission. 
Osuna et al.52, using male and female rhesus (RM) and 
cynomolgus (CM) monkeys evaluated the dynamics of 
ZIKV in blood, cerebrospinal fluid and mucosal secretions. 
They have also evaluated the ZIKV distribution in tissues 
in parallel with immune responses during the acute 
infection monitored for 4 weeks post-infection. Low levels 
of ZIKV RNA were detected in vaginal swab samples 
and cervicovaginal lavage contrasting with high levels of 
ZIKV in the uterus and ovaries. Hirsch et al.59 have also 
developed a RMs model inoculating ZIKV subcutaneously.
They were divided into three cohorts: cohort 1 was infected 
with three different subcutaneously doses; cohorts 2 and 3 
were infected with the same dose but euthanized animals 
in different times to analyze tissues. All the infected 
animals presented with symptoms compatible with ZIKV 
infection. In cohort 2, viral RNA was found in the uterusand 
in cohort 1, viral RNA was detected in the uterus and 
vagina, even though at different times and inoculation 
doses. Both results suggested potential female-to-male 
sexual transmission and have also contributed to evidence 
the possibility of viral infection in both, LGT and UGT. 
However, it is not possible to predict the required viral dose 
and time of infection involved in sexual transmission, as 
well as infection of different FGT parts. 
Haddow et al.57 developed a sexual transmission 
risk model to study infection after sexual intercourse 
byinoculating ZIKV into the vaginal and rectal canal of 16 
adult macaques. For the intravaginal inoculation, four female 
RMs and four female CMs were used. All macaques were 
monitored and daily evaluatedfor symptomatology during 
28 days post-infection (dpi). After intravaginal inoculation, 
50% of the RMs and 50% of the CMs had viremia, and 
after 15 dpi, they had seroconverted. On the other hand, 
75% of the RMs and 100% of the CMs had viremia after 
intrarectal ZIKV inoculation. Although intravaginal and 
intrarectal exposure to ZIKV in both NHP species caused 
infection, the signs and symptoms of clinical disease were 
not observed. Thisstudy demonstrated that ZIKV sexual 
transmission through intravaginal and intrarectal routes is 
possible, indicating sexual intercourse as a mechanism of 
viral transmission in the absence of mosquitoes can possibly 
introduce the disease in non-epidemic areas. However, 
this study did not contribute to the understanding of ZIKV 
infection in FGT, since the presence of the virus in both, 
LGT and UGT, was not evaluated.
Another model of vaginal transmission in NHPs 
was developed by Carroll et al.41 using only RMs and 
intravaginal inoculations. ZIKV was readily transmitted 
to mature cycling female RMs by intravaginal inoculation. 
However, susceptibility varied between individual RMs, 
with 1 to 8 intravaginal inoculations required to establish 
infection. After treatment with Depo-Provera, a widely used 
progestin contraceptive, two RMs that had initially resisted 
eight intravaginal ZIKV inoculations, became infected after 
one inoculation. Thus, Depo-Provera seemed to enhance the 
susceptibility to ZIKV vaginal transmission. Unexpectedly, 
the kinetics of virus replication and dissemination after 
intravaginal ZIKV inoculation were markedly different 
from RMs infected with ZIKV by subcutaneousvirus 
inoculation. In intravaginally inoculated RMs, plasma 
viral RNA was only detected after several days and viral 
RNA shedding from FGT (cervicovaginal lavages) was 
found in all six animals. Furthermore, after intravaginal 
transmission, ZIKV RNA shedding in FGT secretions was 
detected before or simultaneously with plasma viral RNA 
and persisted for the same period of time. Additionally, to 
better understand ZIKV tissue tropism, ZIKV RNA levels 
in tissues of all six RMs infected with ZIKV by intravaginal 
inoculation were determined. ZIKV RNA was detected 
in the vagina, cervix, uterus, ovaries and genital lymph 
nodes. These results corroborate the conclusion that ZIKV 
preferentially replicates in FGT after vaginal transmission, 
but not after subcutaneous inoculation transmission, raising 
the possibility that there is enhanced fetal infection and 
tissue damage after ZIKV vaginal transmission as compared 
to viral transmission by mosquitoes. 
The results of NHPs studies suggest that ZIKV can 
replicate in FGT after intravaginal inoculation more than 
after subcutaneous inoculation. Therefore, it seems that 
depending on ZIKV transmission mode, the infection has 
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a different behavior. In models of mosquitoes transmission, 
there were low levels of ZIKV RNA in the cervical and 
vaginal secretions, which were opposed to models of 
sexual transmission. However, in tissues such as the uterus, 
ZIKV RNA levels were high until 28 dpi in RMs after 
subcutaneous viral inoculation, suggesting an additional 
potential risk to pregnancy. Finally, it was evidenced that 
the use of contraceptives represent an additional risk factor 
for ZIKV vaginal transmission. However, it is not known 
whether this can actually happen in humans.
In vivo ZIKV models in FGT of non-pregnant small 
animals
Several studies have shown that immune competent 
mice are refractory to ZIKV infection51,54. Therefore, 
researchers have used immune compromised animals 
to study ZIKV infection and dissemination. In this way, 
some researchers have used isogenic mice strains such as 
C57BL/6 mice28,53,55,56,61,62; Axl-/-, Mertk-/-, Axl-/- Mertk-/-, 
and Axl-/- Tyro3-/- mice58; Rag-/- and Ifnar1-/- mice60 or the 
immunodeficient AG129 (deficiency in the type-I IFNAR 
and type-II IFNGR interferon receptors) and the A129 
(deficiency in the type-I interferon receptor) mice38,40,55 
to facilitate ZIKV infection, dissemination and study the 
presence of ZIKV in FGT and other tissues/fluids.
Four studies were performed in mice based on their 
hormonal status. Tang et al.55 developed a model of 
ZIKV administration into the vaginas of AG129 and 
LysMCre+IFNARfl/flC57BL/6 mice after induction of 
diestrus and estrus-like phases, respectively. Mice infected 
during the estrus-like phase were resistant to vaginal 
infection. In contrast, when infected during the diestrus-
like phase, AG129 mice succumbed to infection, whereas 
LysMCre+IFNARfl/fl mice experienced transient illness. 
Patency of transgenital transmission (TGT) in diestrus-
like mice was evidenced by detecting viremia and ZIKV 
replication in the spleen and the brain, and viral RNA 
persistence in vaginal washes as late as 10 dpi. This study 
indicated that intravaginal ZIKV administration can cause 
TGT, hormonal changes in FGT-dependent transmission 
and ZIKV replication and persistence in FGT for several 
days. Scott et al.61 evaluated the immune protection against 
an intravaginal ZIKV challenge after previous subcutaneous 
infection to evaluate the protection against reinfection with 
a homologous virus, considering that most ZIKV-infected 
mice are at risk of re-exposure to the same or to a similar 
ZIKV strain. WT C57BL/6 mice were first injected with 
depot medroxyprogesterone acetate (DMPA) to force 
females into the diestrus phase of the estrous cycle. One 
day prior to infection, mice were intraperitoneally treated 
with an anti-IFNAR1 monoclonal antibody or with an 
isotype control monoclonal antibody (mAb). DMPA-treated 
mice were intravaginally inoculated with ZIKV. In animals 
treated with anti-IFNAR1 mAb, infectious ZIKV was 
detected in the vaginal lumen beginning on 1 dpi until 9 dpi. 
Infectious ZIKV was also detected in the vaginal lumen of 
mice treated with the isotype control antibody, although 
the amount was less than and lasted for a shorter period of 
time in comparison to animals treated with the anti-IFNAR1 
mAb. Remarkably, infectious ZIKV was detected in the 
vaginal tissue at relatively similar levels in the isotype 
control and anti-IFNAR1 mAb-treated animals, which is 
consistent with the observation of IFN type I responses 
dampened in this tissue. In contrast to the vaginal results, 
differences were observed in the spread of ZIKV throughout 
FGT in isotype controls and in anti-IFNAR1 mAb-treated 
mice. ZIKV was detected in both, lower (vagina and cervix) 
and upper (uterine horns and ovaries) FGT of most mice 
treated with anti-IFNAR1 mAb, whereas only a small 
subset of animals treated with the isotype control mAb 
had ZIKV in the cervix, with none in the uterine horn or 
ovaries. In all FGT tissues, infectious viruses were cleared 
almost completely by 10 dpi, regardless of anti-IFNAR1 
mAb treatment. The distribution of virally infected cells 
by in situ hybridization (ISH) with ZIKV-specific probes 
in the lower (vagina) and upper (uterine horns) FGT 
from uninfected or ZIKV-infected animals treated with 
anti-IFNAR1 Ab was examined. The majority of ZIKV 
RNA in the vagina was found in the luminal edge of the 
epithelium, suggesting the sloughing of dead cells. In the 
uterine horns, ZIKV RNA was detected in patches of cells 
throughout the tissue parenchyma. Thus, these data show 
that, while immunocompetent C57BL/6 mice treated with 
isotype control antibodies supported the viral replication 
invagina after genital infection, dissemination to UGT 
required suppression of type I IFN response.
The third study that evaluated ZIKV infection and 
host responses in tissues of FGT was conducted by 
Caine et al.28. Initial experiments in primary human vaginal 
and cervical epithelial cells demonstrated that IFN-β or 
IFN-λ treatment induce transcriptional programs that 
inhibit ZIKV infection. By performing studies in hormone-
synchronized, non-pregnant, ovariectomized (OVX) female 
mice, the resistance to intravaginal ZIKV infection during 
the estradiol-high estrous phase and susceptibility during the 
progesterone-high, diestrus phase41,55,61 were confirmed. The 
study observed that estradiol-treated mice were protected 
against intravaginal ZIKV infection, independently of 
IFN-α/β or IFN-λ signaling. In contrast, mice lacking 
IFN-λ signaling sustained greater FGT infection after 
progesteroneadministration. Exogenous IFN-λ treatment 
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confers an antiviral effect when mice received both, 
estradiol and progesterone, but not progesterone alone. 
According to the authors, these results identified a 
hormonal stage-dependent role of IFN-λ in controlling 
FGT ZIKV infection suggesting a way to minimize ZIKV 
sexual transmission in women. Khan et al.53, using the 
lymphocytic choriomeningitis virus (LCMV) and ZIKV in 
C57BL/6NCr CD45.2+ WT mice, showed that these viruses 
replicate in the vaginal mucosa with minimal induction of 
antiviral interferon and inflammatory response, causing 
dampened innate-mediated control of viral replication and 
failure of local antigen-presenting cells (APCs) to reach 
maturity. All the female mice in all the infection groups 
or the uninfected group were injected with Depo-Provera. 
Enhancement of innate-mediated inflammation in the 
vaginal mucosa rescued this phenotype and completely 
inhibited ZIKV replication. To better understand how this 
dampened innate immune activation in lower FGT may 
also affect the adaptive immunity, CD8 T cell responses 
using vaginal LCMV infection were modeled. They showed 
that the lack of APC maturation in the vaginal mucosa 
leads to a delay in CD8 T cell activation in the draining 
lymph nodes, hindering the timely appearance of effector 
CD8 T cells in the vaginal mucosa, further delaying the 
viral control in this tissue. The study demonstrated that 
the vaginal tissue is exceptionally vulnerable to infection 
by RNA viruses, providing a conceptual framework for 
the male-to-female sexual transmission observed in ZIKV 
infections. Taken together, the results of these four studies 
could indicate that hormones can influence the natural 
history of ZIKV infection in women, which is in agreement 
with the results of Carroll et al.41 in NHPs discussed above. 
This is interesting considering that women of reproductive 
age are usually under the influence of endogenous and 
exogenous hormones and could consequently present 
with pronounced ZIKV infections symptoms. In addition, 
according to these results concerning the importance of 
progesterone in the development of LGT ZIKV infection, 
one can hypothesize that both, women in the second phase 
of the menstrual cycle (luteal phase) and pregnant women, 
who are under the action of high progesterone levels, 
could be more susceptible to ZIKV genital infection due 
to rodents’ epithelial and cervical vaginal stroma responses 
to sexual steroids, which are similar to those in humans50. 
Progesterone induces the diestrus phase of the estrous 
cycle in rats, which is similar to the luteal phase of the 
menstrual cycle and pregnancy, in which intermediate 
epithelial squamous cells (ICs) predominate. Thus, ZIKV 
could have a higher affinity for vaginal and ectocervical 
ICs, or the vaginal environment with the predominance of 
ICs could favor ZIKV infection (Figure 2). However, this 
hypothesis can only be clarified by studies on women with 
LGT ZIKV infections. 
In addition to the study of Scott et al.61 described 
earlier, four other studies detected ZIKV in mice ovaries. 
Dowall et al.38 studied the effect of ZIKV infection in 
type I IFN receptor-deficient A129 female mice. They 
were subcutaneously injected with a ZIKV strain isolated 
from A. africanus mosquitoes to develop an adult model 
simulating a natural route of infection. They compared the 
A129 and 129Sv/Ev (WT strain) and could observe that 
A129 mice were susceptible to ZIKV infection, while all 
Figure 2 - Schematic representation of the possible role of progesterone in the development of ZIKV infection in the lower genital 
tract, according to animal studies. The responses of rodent epithelium and cervical vaginal stroma to sex steroids are similar to 
those of humans. Progesterone induces the diestrus phase of the estrous cycle in rats, which is similar to the luteal phase of the 
menstrual cycle and pregnancy, in which intermediate epithelial squamous cells (IC) predominate. ZIKV could have a higher affinity 
for vaginal and ectocervical IC, or the vaginal environment with predominance of IC could favor infection with this virus. BC: basal 
cells; PC: parabasal cells; SC: superficial cells.
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WT 129Sv/Ev survived the entire period of study, as did the 
group who received only PBS injections (control group). 
A129 mice developed severe symptoms with widespread 
viral RNA detection in the blood, brain, spleen, liver and 
ovaries. Histological changes were also striking in these 
animals. 129Sv/Ev mice developed no clinical symptoms 
or histological changes, despite viral RNA being detected 
in the blood, spleen and ovaries, albeit at lower levels than 
those seen in A129 mice. Duggal et al.40, studied viral 
dissemination to FGT that was assessed in IFN-α/β and -γ 
receptor knockout AG129 female mice exposed to ZIKV 
by subcutaneous inoculation, intravaginal inoculation, 
or sexual transmission from AG129-male infected mice. 
Sexual transmission resulted in significantly higher 
morbidity and mortality in females and higher ZIKV 
titers in FGT as compared to subcutaneous or intravaginal 
inoculation. The greater contribution of this study with 
respect to ZIKV infection in FGT of non-pregnant females 
was that ovaries from sexually-infected females contained 
ZIKV RNA within the ovarian follicles. Broughton et al.56 
inoculated C57BL/6 female mice subcutaneously with 
ZIKV and collected ovaries from infected and control mice 
on 7, 14 and 21 dpi. They performed RT-PCR to determine 
the viral load and detected ZIKV RNA at all time points 
in infected mice. Ovarian titers were higher than the ones 
found in serum samples. Caine et al.62 characterized ZIKV 
infection and the ensuing immune response in the ovary 
using a murine model (WT and congenic CD8−/− and 
TCRβδ−/− C57BL/6) and found that animals can be acutely 
infected. On 7 dpi, CD4+ and CD8+ T cells had infiltrated 
the ovary causing oophoritis, with detectable ZIKV-specific 
CD8+ T cells. Infection and inflammation were associated 
to dying cells during the acute stage of infection. In contrast 
to results in the testis27-29, excessive and persistent tissue 
damage was not seen in ZIKV-infected mice ovaries, and 
persistent viral RNA was not detected in most animals on 
90 dpi. The resolution of infection and tissue injury were 
associated to the lack of detrimental long-term impact on 
fertility or ovarian reserve. Thus, even though the ovary is 
vulnerable to acute ZIKV infection and inflammation, long-
term effects on fertility were not observed, at least in mice. 
Hastings et al.58 investigated the requirement of Tyro 3, 
Axl and Mer (TAM) receptors for ZIKV infection by 
inoculating the virus through different routes and comparing 
viral replication in WT mice versus Axl-/-, Mertk-/-, Axl-/- 
Mertk-/-, and Axl-/- Tyro3-/- mice, in different organs. 
TAM receptors are candidates of ZIKV entry receptors. 
The researchers demonstrated that TAM receptors are 
not required for ZIKV infection throughsubcutaneous, 
transplacental, vaginal or intracranial routes. ZIKV 
replication was not affected by the absence of TAM 
receptors in the spleen, placenta, vagina and the brain. 
These results indicate that, in mice, TAM receptors are not 
required for ZIKV infection.
Finally, Winkler et al.60 studied both, ZIKV sexual 
transmission (STx) and vertical transmission (VTx) using 
anti-IFNAR1-treatment of Rag1 -/- (AIR) mice. These mice 
have suppressed type I IFN responses and lack adaptive 
immune responses, leading to a prolonged infection prior to 
clinical disease. The STx of ZIKV from infected AIR males 
to naive Ifnar1 -/- females was observed with a higher than 
50% incidence and infection observed in the vaginal tract 
at early time points. By mating Ifnar1-/-, they have also 
observed that ZIKV infection of the vaginal tract correlates 
with development of clinical disease.
Studies presented in this section showed that small 
animals, mainly mice, are good models for ZIKV infection 
and that these viruses have tropism for FGT cells, tissues 
and organs. The results have also indicated that the natural 
history of ZIKV infection in females is directly influenced 
by hormones, components of the innate and the adaptive 
immune system. It is interesting to observe that the antiviral 
IFN response and inflammation are minimally induced in 
LGT. This provides an opportunity for ZIKV replication in 
the vaginal mucosa and dissemination to other FGT parts, 
damaging tissues and the fetus.
In vitro ZIKV cellular models in FGT studies
Chen et al.63 cultured uterine fibroblasts inoculated with 
two different ZIKV strains (VR-84 or VR-1843). Their 
results indicated that uterine fibroblasts are susceptible 
to ZIKV infection and the uterus may act as a viral 
pathway during heterosexual intercourse. In addition, 
the study of Pagani et al.64 showed that primary human 
endometrial stromal cells (HESCs) are highly permissive 
to ZIKV infection and support in vitro viral replication. 
ZIKV productive infection has also occurred in a human 
endometrial stromal cell line (T-HESC) together with the 
induction of IFN-β and of IFN-stimulated genes.
Chan et al.65 characterized differential cell lines 
susceptibility using 18 human and 15 non-human cell 
lines and two ZIKV isolates (human and primate), as well 
as DENV type 2 (DENV-2). Considering FGT, the cell 
lines were HeLa (cervical adenocarcinoma) and HOSE6-3 
(ovarian surface epithelium). A ≥ 2 log increase in the mean 
viral load (P<0.01) within 5 dpi was observed in both cell 
lines. The highest mean viral load (≥10 log copies/mL) 
was observed in the HeLa cell line that has also shown a 
clear ZIKV-NS1 protein expression in addition to a high 
viral load. Although HOSE6-3 cells showed high mean 
viral loads in RT-PCR, ZIKV-NS1 protein expression was 
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consistently found in ≤ 5% of infected cells. Comparatively, 
none of the placental and genital tract cell lines allowed 
efficient DENV-2 replication. 
Fink et al.66 studied if Arbidol (ARB, umifenovir) 
could inhibit different ZIKV isolates. The efficacy of ARB 
in primary cell lines was evaluated by infecting primary 
human vaginal (HVE2) and primary endocervical (ENDO) 
and ectocervical (ECTO) epithelial cells with ZIKV in the 
presence and absence of ARB pretreatment. In relation to 
FGT cells, HVE2, ENDO and ECTO cells were markedly 
infected by ZIKV. ARB treatment (20 μM) resulted in 
significant suppression of ZIKV protein synthesis. Finally, 
ZIKV RNA expression in primary vaginal and cervical 
epithelial cells from different ZIKV strains-infected donors 
has also been suppressed by ARB.
To begin studies addressing the impact of selected 
human vaginal microbiome (VMB) communities on ZIKV 
infection and HSV-2 infection, Amerson-Brown et al.67 
employed their polarized vaginal epithelial cell (VEC) 
multilayer culture model. Taken together, results confirmed 
that, after ZIKV infection, VECs supported viral replication 
before being systemically released into the basal chamber. 
In addition, ZIKV infection did not cause significant 
changes in established VMBs.
Cagno et al.68 investigated the tropism of Asian and 
African ZIKV strains using human-derived neural, vaginal, 
intestinal and respiratory tissues. Both ZIKV strains were 
able to grow in all the tissues tested, although with different 
efficiencies (7.3 log RNA copies released apically in vaginal 
tissues versus 9.8 log RNA copies released in intestinal 
tissues) and without the need of major adaptation. The 
results underlined that ZIKV tropism may be broader than 
expected in humans and highlighted the need to better 
explore all possible virus shedding sites and transmission 
routes.
Müller et al.69 analyzed the effect of semen on 
ZIKV infection of anogenital cells and tissues. ZIKV 
replicated in all the analyzed cell lines, primary cells and 
endometrial or vaginal tissues. However, in the presence 
of semen, ZIKV infection and other flaviviruses were 
potently inhibited. More specifically, to clarify whether 
anogenital cells support the productive infection, primary 
endometrial stromal fibroblasts (eSFs) and human foreskin 
fibroblasts (HFFs), as well as cell lines derived from the 
cervix (HeLa), endometrium (TZM-bl), colon (SW480 
and T-84) and ovaries (OVCAR-3 and SKOV3) were 
inoculated with ZIKV. Confocal microscopy demonstrated 
that the analyzed cell types were infected as assessed by 
E protein expression. All the infected cells released viral 
RNA and infectious viruses. Among the tested cell lines, 
viral replication was less efficient in SKOV3 and T-84 cells 
and the most efficient in SW480, HeLa and OVCAR-3 
cells; eSFs and HFFs supported efficient levels of ZIKV 
replication. Moreover, to analyze whether ZIKV can also 
replicate in FGT intact tissues, surgically removed vaginal 
(VT) or endometrial (ET) tissues were cut into blocks and 
infected with ZIKV, and a productive viral infection was 
established in the majority of VTs and ETs analyzed. The 
absolute titers and kinetics of replication, however, varied 
between experiments and donors. 
Two other studies showed ZIKV tropism for HeLa 
cells. Among them, Silva et al.70 infected 10 human and 
4 non-human cell lines with two African (IbH30656 and 
MR766) and two Asian (PRVABC59 and H/FP/2013) 
ZIKV strains. In the context of FGT, only HeLa cells were 
evaluated. Among the human cell lines, all were permissive 
to ZIKV infection. However, 293T and HeLa cells showed 
differential susceptibilities to African strains. On the other 
hand, considering that previous studies have shown that 
mosquito-transmitted flaviviruses, including yellow fever, 
JEV, and WNV, could be attenuated by serial HeLa cells 
passages, Li et al.71 hypothesized that ZIKV could also be 
attenuated after passages in HeLa cells. A human isolate 
from a recent ZIKV epidemic was subjected to serial 
passages in HeLa cells resulting in attenuated in vitro 
replication in both, Vero and A549 cells. These data showed 
that, similarly to other mosquito-borne flaviviruses, ZIKV 
is attenuated after passages in HeLa cells. 
Finally, to characterize the innate immune response 
of FGT tissues to ZIKV infections, Caine et al.28 first 
evaluated the effect of recombinant IFN-β and IFN-λ on 
ZIKV infection in primary human vaginal epithelial cells 
(HVECs) obtained from four different donors and primary 
human cervical epithelial cells (HCECs) obtained from 
three donors. The results showed that HVECs and HCECs 
treatments with IFN-α/β or IFN-λ induced host defense 
transcriptional signatures and inhibited ZIKV infection. The 
study has also assessed the effects of IFNs on intravaginal 
FGT infections using ovariectomized mice treated with 
reproductive hormones. 
Although few in vitro studies have been performed, 
they have provided important evidence regarding tropism 
of ZIKV for LGT and UGT. However, considering that 
few in vitro studies have evaluated the interaction between 
ZIKV and FGT cells, new studies with organ-technology 
and organ-specific chip models are still urgently needed. 
Assisted reproductive technologies (ART) 
recommendations
Due to the persistence of ZIKV RNA in female and 
male genital tracts, specific and essential care are required 
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for couples who have performed or intend to perform ART, 
especially in view of ZIKV’s association to congenital 
microcephaly in newborns. There is a potential risk for 
disease transmission at several ART stages72. However, 
there are no validated molecular biology-based commercial 
tests for ZIKV detection in FGT samples, including oocytes. 
There is a limited understanding on how these test results 
should be interpreted, especially ZIKV RNA detection in 
FGT that does not necessarily indicate the presence of a 
replication-competent or infectious virus. The detection of 
viable infectious ZIKV is only possible using cell culture 
techniques36. Additionally, serological tests do not provide 
furtherinformation, as a negative serological test does not 
exclude the possibility of ZIKV in FGT. Finally, ZIKV 
Immunoglobulin (Ig) M and IgG detection by serological 
tests do have cross-reaction problems with other circulating 
flaviviruses, including dengue73,74. As a result, testing 
on FGT samples is not currently recommend by CDC75 
and WHO20. Therefore, CDC, the European Centers for 
Disease Prevention and Control (ECDC), Food and Drug 
Administration (FDA) and WHO recommendations do 
not directly address non-pregnant women regarding ZIKV 
outbreaks, but recommendations provided for women of 
childbearing age or planning pregnancy apply to the ART 
sector76.
The American Society for Reproductive Medicine 
(ASRM) guidelines77, recommend that males or females 
with a positive viral RT-PCR test result, should deffer the 
treatment of infertility until (i) a subsequent RT-PCR test 
is negative in the couple and (ii) at least 6 months have 
passed from the time of the last positive result. For males 
or females without testing or with a negative RT-PCR 
test result, gamete or embryo cryopreservation have to be 
considered and quarantined until (i) a subsequent RT-PCR is 
negative in the couple and (ii) at least 8 weeks have passed 
from the time of the gamete collection. 
In Brazil, technical criteria were defined for the 
health risk management of cells, germ tissues and human 
embryos intended for therapeutic use in the face of cases 
of ZIKV infection in the country. In summary, ART 
recommendations related to non-pregnant women are78: 
(i) For donors’ and patients’ selection, laboratory tests for 
ZIKV (detection of antibody against ZIKV-IgM) should 
be performed; (ii) For female patients with reactive or 
inconclusive results in serological screening tests to ZIKV, 
the following is recommended: I - Repeat the serological 
test (IgM) after 30 days; or II - Perform a molecular 
biology test for ZIKV markers at any time; (iii) Gametes 
or germ tissues may only be collected for proper use 
in ART after obtaining non-reactive or negative results 
for ZIKV. 
Therefore, understanding the mechanisms that underlie 
persistent ZIKV infections in non-pregnant women is 
crucial to develop guidelines, effective vaccinesand 
therapies. Furthermore, the development and validation 
of commercial tests based on molecular technology for 
ZIKV detection in FGT samples, including oocytes, are 
also essential in new ARTs’ guidelines. 
CONCLUSION 
This review summarized the current information on 
the impact of ZIKV infections in FGT of non-pregnant 
ZIKV-infected females. There are variations regarding the 
presence and persistence of the virus in lower and upper 
genital samples. However, it is consensual that FGT is the 
place in which ZIKV RNA has been detected, sometimes 
for relatively long periods, even after clearance from blood 
and urine. Studies evaluating the kinetics of the ZIKV in 
FGT of ZIKV-infected non-pregnant women, as well as in 
animal and cellular infection models have shown that, in 
addition to the vagina and cervix, the endometrium, uterus 
and ovaries (oocytes and follicles) can also be involved 
in persistent ZIKV infection. However, little is known 
about the effect of ZIKV on female reproductive health. 
FGT may possibly act as a sanctuary for ZIKV survival, 
allowing and extending the risk of sexual transmission. 
This evidence supports the recommendation of safe sex 
practices for women returning from areas with ongoing 
ZIKV transmission. Due to the scarce and non consensual 
literature, new studies are needed to establish the natural 
history of ZIKV transmission, pathogenesis and methods to 
detect ZIKV in FGT. In addition, future studies may clarify 
the impact of ZIKV infection on female reproductive health.
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